Stock AIMD AINOS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ainos, Inc.

Equities

AIMD

US00902F3038

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.03 USD -0.97% Intraday chart for Ainos, Inc. +1.98% -49.76%
Mar. 19 Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer CI
Mar. 15 Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer
CI
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer
CI
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
MT
Top Premarket Decliners
MT
Ainos : Reports Full Year 2023 Financial Results - Form 8-K
PU
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Top Premarket Gainers
MT
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial
MT
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms
CI
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
AQ
Ainos Announces $1.75 Million Follow-On Funding
AQ
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation
CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected
MT
Ainos Regains Compliance With Nasdaq Listing Rule
MT
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell
CI
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary
CI
Ainos, Inc. Announces Stock Consolidation
AQ
Ainos : Private Placement - Form 8-K
PU
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data
MT
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AIMD Stock
  4. News Ainos, Inc.